bluebird bio Inc (NASDAQ:BLUE) Director Daniel Lynch sold 237 shares of the business’s stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $100.07, for a total transaction of $23,716.59. Following the completion of the transaction, the director now directly owns 1,637 shares of the company’s stock, valued at approximately $163,814.59. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Daniel Lynch also recently made the following trade(s):
- On Wednesday, February 15th, Daniel Lynch sold 150 shares of bluebird bio stock. The stock was sold at an average price of $80.22, for a total transaction of $12,033.00.
- On Tuesday, February 14th, Daniel Lynch sold 850 shares of bluebird bio stock. The stock was sold at an average price of $80.01, for a total transaction of $68,008.50.
- On Friday, January 27th, Daniel Lynch sold 1,000 shares of bluebird bio stock. The stock was sold at an average price of $70.09, for a total transaction of $70,090.00.
bluebird bio Inc (NASDAQ:BLUE) traded down 0.97% during midday trading on Monday, reaching $91.50. 654,428 shares of the company were exchanged. The company has a 50-day moving average of $81.50 and a 200 day moving average of $67.35. The firm’s market capitalization is $3.74 billion. bluebird bio Inc has a 52 week low of $35.37 and a 52 week high of $100.40.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, February 22nd. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($1.86) by $0.02. bluebird bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The business had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.76 million. During the same period last year, the business posted ($1.29) EPS. bluebird bio’s revenue was up 5.4% on a year-over-year basis. Equities analysts predict that bluebird bio Inc will post ($7.31) earnings per share for the current year.
var userip;Your IP Address: document.write(userip);
Several large investors have recently modified their holdings of the company. Norges Bank acquired a new stake in shares of bluebird bio during the fourth quarter valued at $22,940,000. Advantage Investment Management LLC acquired a new stake in shares of bluebird bio during the fourth quarter valued at $159,000. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of bluebird bio during the fourth quarter valued at $1,869,000. Armistice Capital LLC acquired a new stake in shares of bluebird bio during the fourth quarter valued at $2,468,000. Finally, Clough Capital Partners L P acquired a new stake in shares of bluebird bio during the fourth quarter valued at $555,000.
BLUE has been the subject of a number of recent research reports. Morgan Stanley boosted their price objective on shares of bluebird bio from $58.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 1st. Maxim Group lowered shares of bluebird bio from a “buy” rating to a “hold” rating and set a $87.00 price objective for the company. in a report on Monday, February 27th. They noted that the move was a valuation call. JPMorgan Chase & Co. restated a “buy” rating and issued a $120.00 price objective on shares of bluebird bio in a report on Wednesday, December 7th. Roth Capital restated a “neutral” rating and issued a $71.00 price objective (down from $87.00) on shares of bluebird bio in a report on Monday, February 6th. Finally, Zacks Investment Research lowered shares of bluebird bio from a “buy” rating to a “hold” rating in a report on Thursday, February 9th. One analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the stock. bluebird bio presently has an average rating of “Buy” and a consensus target price of $84.53.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.